CSIMarket
 


Cytokinetics Incorporated  (CYTK)
Other Ticker:  
 

Cumulative Cytokinetics Incorporated's Working Capital Ratio for Trailing Twelve Months Period

CYTK's Working Capital Ratio for Trailing Twelve Months Period and Current Assets, Current Liabilities growth


Select the Comparisons : Select the Ratio:

CYTK Working Capital Ratio for Trailing Twelve Months Period

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities Growth 0.08 % -4.99 % 16.43 % 25.95 % -10.17 %
Y / Y Current Assets Growth -36.51 % -2.6 % 9.16 % 48.45 % 78.66 %
Working Capital Ratio for Trailing Twelve Months Period 10.79 12.12 12.06 12.25 11.9
Total Ranking # 342 # 317 # 357 # 421 # 488
Seq. Current Liabilities Growth 21.18 % -18.11 % -15.09 % 18.78 % 15.04 %
Seq. Current Assets Growth -4.29 % -13.82 % -14.41 % -10.07 % 46.83 %


Working Capital Ratio for Trailing Twelve Months Period Comment for 12 Months ending at Sep 30 2023
On the trailing twelve months basis Due to growth in Current Liabilities in the III. Quarter to $60 millions, average cumulative Working Capital Ratio for Trailing Twelve Months Period decreased to 10.79 below Cytokinetics Incorporated average Working Capital Ratio for Trailing Twelve Months Period.
Working Capital Ratio for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies operatig within Major Pharmaceutical Preparations industry 125 other companies have achieved higher Working Capital Ratio for Trailing Twelve Months Period than Cytokinetics Incorporated. While overall ranking remained unchanged compare to previous quarter at no. .

What is Working Capital Ratio?
More about CYTK
Working Capital Ratio CYTK in the most recent quarter
Working Capital Ratio for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 126
Sector # 199
S&P 500 # 302


Working Capital Ratio for Trailing Twelve Months Period Statistics
High Average Low
13.16 7.3 2.73
(Mar 31 2021)   (March 31, 2014)




Companies with similar average Working Capital Ratio for Trailing Twelve Months Period for 12 months ending Sep 30 2023, within Major Pharmaceutical Preparations Industry Working Capital Ratio for Trailing Twelve Months Period
Gh Research Plc  29.57 
Dice Therapeutics Inc   29.08 
Atossa Therapeutics Inc   28.99 
Design Therapeutics Inc   28.09 
Eliem Therapeutics Inc   27.09 
Mineralys Therapeutics Inc   27.08 
Briacell Therapeutics Corp   26.16 
Imago Biosciences Inc   25.95 
Xenon Pharmaceuticals Inc   25.51 
Theseus Pharmaceuticals Inc   25.00 
Terns Pharmaceuticals Inc   24.47 
Rezolute Inc   24.17 
Cyteir Therapeutics Inc   24.12 
Eqrx Inc   24.02 
Astria Therapeutics Inc   23.94 
Belite Bio Inc  23.14 
Artelo Biosciences Inc   22.20 
Disc Medicine Inc   22.15 
Diamedica Therapeutics Inc   21.10 
Savara Inc   21.02 
Minerva Neurosciences Inc   21.00 
Prometheus Biosciences Inc   20.91 
Kezar Life Sciences Inc   20.76 
Akero Therapeutics Inc   20.69 
Janux Therapeutics Inc   20.57 
Edgewise Therapeutics inc   20.54 
Pmv Pharmaceuticals Inc   20.33 
Nextcure Inc   20.32 
Kura Oncology Inc   19.97 
Lantern Pharma Inc   19.50 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com